| Contact |
General |
Specializations in Countries |
Contribution to the Global Plan |
Declaration |
View this partner's profile
Organization Contact Information |
| Name: |
JF Healthcare |
| Street 1: |
Room 101 Plant 5-7#, CECEP Jiangxi Low Carbon Park Nanchang City, Jiangxi Province China |
| Street 2: |
|
| City: |
Nanchang |
| Province: |
Jiangxi |
| Post Code: |
330047 |
| Country: |
China |
| Phone: |
+86 17521646226 |
| Organization Email: |
nina.suen@qq.com |
| Web Site: |
http://intl.jfhealthcare.com/en/ |
| Other Online Presence: |
|
Focal Point Contact Information |
| Salutation: |
Ms |
| First Name: |
Nina |
| Last Name: |
Suen |
| Title: |
Product Manager |
| Email: |
nina.suen@qq.com |
| Phone: |
+86 17521646226 |
|
Alternate Focal Point Contact Information |
| Salutation: |
Dr |
| First Name: |
Wei |
| Last Name: |
Liu |
| Title: |
Chief Medical Officer |
| Email: |
whhzliuwei@163.com |
| Phone: |
+86 13588000511 |
|
General Information |
| Board Constituency: |
None |
| Is your organization legally registered in your country: |
Yes |
| If yes, please enter your registration number: |
91360106343240866K |
| Organization Type - Primary: |
Private Sector |
| Organization Type - Secondary: |
Company |
| Organization Description: |
Specializing in artificial intelligence (AI) applications, JF Healthcare has developed an advanced AI chest X-ray screening system. This system seamlessly integrates with digital chest radiograph (DR) devices, automatically collecting DICOM imaging data. JF Healthcare's focus on leveraging AI technology has proven to be instrumental in enhancing diagnostic accuracy and efficiency.
The significant global health challenge posed by Tuberculosis (TB) has captured JF Healthcare's attention, aligning with its mission to address critical healthcare issues. Recognizing the substantial burden of TB, especially in China, JF Healthcare has directed its technological expertise towards developing AI-driven solutions specifically tailored for TB screening. The company is driven by a commitment to improving the diagnosis and management of TB, thereby contributing to broader public health initiatives.
3)JF Healthcare has implemented a comprehensive AI chest X-ray screening system designed to augment TB control efforts. The system employs an integrated approach, from image quality control modules to anatomy-specific shooting guidance, ensuring the production of high-quality diagnostic images. The AI algorithm module analyzes these images, providing a probability score of TB and highlighting suspected lesions. By demonstrating equivalent diagnostic performance to radiologists in large academic teaching hospitals, JF Healthcare's AI TB screening system significantly enhances both the efficiency and quality of TB care. Moreover, the company has established a regional network mode, connecting smart workstations to form a network that assists physicians in primary care hospitals to swiftly identify TB patients. This coordinated approach improves efficiency and collaboration within the tiered healthcare system, contributing to a more effective TB control network. JF Healthcare is dedicated to supporting primary care through advanced AI telemedicine and other technologies, ensuring accessible and affordable diagnostic serv |
| |
| Do you know about the UNHLM declaration: |
No |
Specializations / Areas of Work |
Provision of drugs, diagnostics and commodities
|
Other Organization Information |
| Total number of staff in your organization: |
51 - 99 |
| Number of full-time staff who are directly involved with TB: |
26 - 50 |
| Number of part-time staff who are directly involved with TB: |
0 |
| Number of volunteers who are directly involved with TB: |
0 |
| |
| How did you hear about the Stop TB Partnership: |
Attendance at a TB related event |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: |
Beijing Tuberculosis Diagnosis and Treatment Technology Innovation Alliance |
| Why do you wish join the Stop TB Partnership: |
Involvement in Stop TB Working Groups |
| |
| Are you a member of a Stop TB national partnership: |
No |
| Are you in contact with your national TB programme: |
Yes |
| Please tell us how your organization is contributing to your country's national TB control plan: |
| Not only do we have an AI monitoring and early warning tuberculosis system, but we have also successfully screened out latent tuberculosis, and have successfully conducted screening in universities and communities in more than 12 provinces. The average AI screening speed is 0.2 seconds per time. More than 1.65 million chest X-rays have been read. The development of JF’S TB AI detection solution was granted and supported by the State Key Project of Science and Technology and received category III approval from the National Medical Products Administration(NMPA) at the end of 2022. Obtain EU CE certification in September 2023. |
| |
Geographical Reach |
| Which country is your headquarters located in: |
China |
Which countries do you do operate in:
(This includes countries you are conducting activities in) |
Nigeria
|
Contribution |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: |
New Diagnostics:
Early detection and early treatment are effective ways to end TB. Our AI TB screening product has surpassed human doctors in international competitions. In actual use, AI has even detected patients with unruptured effusions. It has undergone a large number of tests in 2069+ hospitals. In the actual test, a total of approximately 1.65 million images were read, and the sensitivity and specificity were effectively verified.
|
Declaration |
Declaration of interests:
No conflicts of interest were delacred.
|
| Application date: |
March 6, 2024 |
| Last updated: |
March 6, 2024 |
|
